▶ 調査レポート

血友病A・B組換え因子補充療法の世界市場（～2026年）
• 英文タイトル：Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, Status and Forecast 2020-2026

QYResearchが調査・発行した産業分析レポートです。血友病A・B組換え因子補充療法の世界市場（～2026年） / Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, Status and Forecast 2020-2026 / MRC2-11QY12158資料のイメージです。• レポートコード：MRC2-11QY12158
• 出版社/出版日：QYResearch / 2020年11月25日
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、94ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：ヘルスケア
• 販売価格（消費税別）
  Single User￥577,200 (USD3,900)▷ お問い合わせ
  Multi User￥865,800 (USD5,850)▷ お問い合わせ
  Enterprise License￥1,154,400 (USD7,800)▷ お問い合わせ
• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
当調査資料は血友病A・B組換え因子補充療法のグローバル市場について調査・分析したレポートです。種類別（血友病A、血友病B）市場規模、用途別（病院、クリニック、外来手術センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別血友病A・B組換え因子補充療法の競争状況、市場シェア
・世界の血友病A・B組換え因子補充療法市場：種類別市場規模 2015年-2020年（血友病A、血友病B）
・世界の血友病A・B組換え因子補充療法市場：種類別市場規模予測 2021年-2026年（血友病A、血友病B）
・世界の血友病A・B組換え因子補充療法市場：用途別市場規模 2015年-2020年（病院、クリニック、外来手術センター）
・世界の血友病A・B組換え因子補充療法市場：用途別市場規模予測 2021年-2026年（病院、クリニック、外来手術センター）
・北米の血友病A・B組換え因子補充療法市場分析：米国、カナダ
・ヨーロッパの血友病A・B組換え因子補充療法市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの血友病A・B組換え因子補充療法市場分析：日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の血友病A・B組換え因子補充療法市場分析：メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの血友病A・B組換え因子補充療法市場分析：トルコ、サウジアラビア、UAE等
・企業情報（企業概要、製品概要、販売量、企業動向）
- 掲載企業（変更可能性あり）：Pfizer、Novo Nordisk、Baxalta、Bayer、Biogen、CSL Behring、Emergent Biosolutions、Spark therapeutics、Uniqure
・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

Haemophilia is a group of inherited genetic disorders which causes abnormal or exaggerated bleeding. It impairs the normal mechanism of blood clotting after an injury. Internal bleeding inside the joint or inside brain is commonly seen in the patients with severe to moderate haemophilia. Its symptoms include bleeding from any site of the body. Internal bleeding is fatal as internal bleeding inside the joint causes joint damage and inside the brain, causes brain damage and seizers. The disease is inherited in an X-linked recessive genetic pattern, therefore males are commonly affected with haemophilia while females are usually carriers of the disease. Haemophilia A is caused by the deficiency of clotting Factor VIII, whereas haemophilia B is caused by the deficiency of Factor IX. It is also known as Christmas disease. The disease management includes factor replacement therapy. Factor replacement therapy is the infusion of factor VIII and IX concentrates through injection to control bleeding. These factor concentrates come from two sources i.e. from human plasma or from genetically engineered cell line made by recombinant DNA technology.

Market Analysis and Insights: Global Hemophilia A and B Recombinant Factor Replacement Therapy Market
The global Hemophilia A and B Recombinant Factor Replacement Therapy market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Hemophilia A and B Recombinant Factor Replacement Therapy Scope and Market Size
Hemophilia A and B Recombinant Factor Replacement Therapy market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hemophilia A and B Recombinant Factor Replacement Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Pfizer
Novo Nordisk
Baxalta
Bayer
Biogen
CSL Behring
Emergent Biosolutions
Spark therapeutics
Uniqure

Market segment by Type, the product can be split into
Haemophilia A
Haemophilia B
Market segment by Application, split into
Hospitals
Clinics
AmbulatorySurgicalCenters

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Hemophilia A and B Recombinant Factor Replacement Therapy Revenue
1.4 Market by Type
1.4.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Haemophilia A
1.4.3 Haemophilia B
1.5 Market by Application
1.5.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 AmbulatorySurgicalCenters
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Perspective (2015-2026)
2.2 Global Hemophilia A and B Recombinant Factor Replacement Therapy Growth Trends by Regions
2.2.1 Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Hemophilia A and B Recombinant Factor Replacement Therapy Historic Market Share by Regions (2015-2020)
2.2.3 Hemophilia A and B Recombinant Factor Replacement Therapy Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Hemophilia A and B Recombinant Factor Replacement Therapy Market Growth Strategy
2.3.6 Primary Interviews with Key Hemophilia A and B Recombinant Factor Replacement Therapy Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Hemophilia A and B Recombinant Factor Replacement Therapy Players by Market Size
3.1.1 Global Top Hemophilia A and B Recombinant Factor Replacement Therapy Players by Revenue (2015-2020)
3.1.2 Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share by Players (2015-2020)
3.1.3 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Concentration Ratio
3.2.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in 2019
3.3 Hemophilia A and B Recombinant Factor Replacement Therapy Key Players Head office and Area Served
3.4 Key Players Hemophilia A and B Recombinant Factor Replacement Therapy Product Solution and Service
3.5 Date of Enter into Hemophilia A and B Recombinant Factor Replacement Therapy Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Historic Market Size by Type (2015-2020)
4.2 Global Hemophilia A and B Recombinant Factor Replacement Therapy Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2015-2020)
5.2 Global Hemophilia A and B Recombinant Factor Replacement Therapy Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size (2015-2020)
6.2 Hemophilia A and B Recombinant Factor Replacement Therapy Key Players in North America (2019-2020)
6.3 North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2015-2020)
6.4 North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2015-2020)

7 Europe
7.1 Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Size (2015-2020)
7.2 Hemophilia A and B Recombinant Factor Replacement Therapy Key Players in Europe (2019-2020)
7.3 Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2015-2020)
7.4 Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2015-2020)

8 China
8.1 China Hemophilia A and B Recombinant Factor Replacement Therapy Market Size (2015-2020)
8.2 Hemophilia A and B Recombinant Factor Replacement Therapy Key Players in China (2019-2020)
8.3 China Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2015-2020)
8.4 China Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2015-2020)

9 Japan
9.1 Japan Hemophilia A and B Recombinant Factor Replacement Therapy Market Size (2015-2020)
9.2 Hemophilia A and B Recombinant Factor Replacement Therapy Key Players in Japan (2019-2020)
9.3 Japan Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2015-2020)
9.4 Japan Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Hemophilia A and B Recombinant Factor Replacement Therapy Market Size (2015-2020)
10.2 Hemophilia A and B Recombinant Factor Replacement Therapy Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2015-2020)
10.4 Southeast Asia Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2015-2020)

11 India
11.1 India Hemophilia A and B Recombinant Factor Replacement Therapy Market Size (2015-2020)
11.2 Hemophilia A and B Recombinant Factor Replacement Therapy Key Players in India (2019-2020)
11.3 India Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2015-2020)
11.4 India Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size (2015-2020)
12.2 Hemophilia A and B Recombinant Factor Replacement Therapy Key Players in Central & South America (2019-2020)
12.3 Central & South America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2015-2020)
12.4 Central & South America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Pfizer
13.1.1 Pfizer Company Details
13.1.2 Pfizer Business Overview
13.1.3 Pfizer Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
13.1.4 Pfizer Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2015-2020))
13.1.5 Pfizer Recent Development
13.2 Novo Nordisk
13.2.1 Novo Nordisk Company Details
13.2.2 Novo Nordisk Business Overview
13.2.3 Novo Nordisk Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
13.2.4 Novo Nordisk Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2015-2020)
13.2.5 Novo Nordisk Recent Development
13.3 Baxalta
13.3.1 Baxalta Company Details
13.3.2 Baxalta Business Overview
13.3.3 Baxalta Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
13.3.4 Baxalta Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2015-2020)
13.3.5 Baxalta Recent Development
13.4 Bayer
13.4.1 Bayer Company Details
13.4.2 Bayer Business Overview
13.4.3 Bayer Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
13.4.4 Bayer Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2015-2020)
13.4.5 Bayer Recent Development
13.5 Biogen
13.5.1 Biogen Company Details
13.5.2 Biogen Business Overview
13.5.3 Biogen Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
13.5.4 Biogen Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2015-2020)
13.5.5 Biogen Recent Development
13.6 CSL Behring
13.6.1 CSL Behring Company Details
13.6.2 CSL Behring Business Overview
13.6.3 CSL Behring Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
13.6.4 CSL Behring Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2015-2020)
13.6.5 CSL Behring Recent Development
13.7 Emergent Biosolutions
13.7.1 Emergent Biosolutions Company Details
13.7.2 Emergent Biosolutions Business Overview
13.7.3 Emergent Biosolutions Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
13.7.4 Emergent Biosolutions Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2015-2020)
13.7.5 Emergent Biosolutions Recent Development
13.8 Spark therapeutics
13.8.1 Spark therapeutics Company Details
13.8.2 Spark therapeutics Business Overview
13.8.3 Spark therapeutics Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
13.8.4 Spark therapeutics Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2015-2020)
13.8.5 Spark therapeutics Recent Development
13.9 Uniqure
13.9.1 Uniqure Company Details
13.9.2 Uniqure Business Overview
13.9.3 Uniqure Hemophilia A and B Recombinant Factor Replacement Therapy Introduction
13.9.4 Uniqure Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2015-2020)
13.9.5 Uniqure Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Hemophilia A and B Recombinant Factor Replacement Therapy Key Market Segments
Table 2. Key Players Covered: Ranking by Hemophilia A and B Recombinant Factor Replacement Therapy Revenue
Table 3. Ranking of Global Top Hemophilia A and B Recombinant Factor Replacement Therapy Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Haemophilia A
Table 6. Key Players of Haemophilia B
Table 7. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 8. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Regions (2015-2020)
Table 11. Global Hemophilia A and B Recombinant Factor Replacement Therapy Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Regions (2021-2026)
Table 13. Market Top Trends
Table 14. Key Drivers: Impact Analysis
Table 15. Key Challenges
Table 16. Hemophilia A and B Recombinant Factor Replacement Therapy Market Growth Strategy
Table 17. Main Points Interviewed from Key Hemophilia A and B Recombinant Factor Replacement Therapy Players
Table 18. Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue by Players (2015-2020) (Million US$)
Table 19. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Players (2015-2020)
Table 20. Global Top Hemophilia A and B Recombinant Factor Replacement Therapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy as of 2019)
Table 21. Global Hemophilia A and B Recombinant Factor Replacement Therapy by Players Market Concentration Ratio (CR5 and HHI)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Hemophilia A and B Recombinant Factor Replacement Therapy Product Solution and Service
Table 24. Date of Enter into Hemophilia A and B Recombinant Factor Replacement Therapy Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2015-2020) (Million US$)
Table 27. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size Share by Type (2015-2020)
Table 28. Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share by Type (2021-2026)
Table 29. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size Share by Application (2015-2020)
Table 30. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2015-2020) (Million US$)
Table 31. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size Share by Application (2021-2026)
Table 32. North America Key Players Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (2019-2020) (Million US$)
Table 33. North America Key Players Hemophilia A and B Recombinant Factor Replacement Therapy Market Share (2019-2020)
Table 34. North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2015-2020) (Million US$)
Table 35. North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Type (2015-2020)
Table 36. North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2015-2020) (Million US$)
Table 37. North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Application (2015-2020)
Table 38. Europe Key Players Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (2019-2020) (Million US$)
Table 39. Europe Key Players Hemophilia A and B Recombinant Factor Replacement Therapy Market Share (2019-2020)
Table 40. Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2015-2020) (Million US$)
Table 41. Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Type (2015-2020)
Table 42. Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2015-2020) (Million US$)
Table 43. Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Application (2015-2020)
Table 44. China Key Players Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (2019-2020) (Million US$)
Table 45. China Key Players Hemophilia A and B Recombinant Factor Replacement Therapy Market Share (2019-2020)
Table 46. China Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2015-2020) (Million US$)
Table 47. China Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Type (2015-2020)
Table 48. China Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2015-2020) (Million US$)
Table 49. China Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Application (2015-2020)
Table 50. Japan Key Players Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (2019-2020) (Million US$)
Table 51. Japan Key Players Hemophilia A and B Recombinant Factor Replacement Therapy Market Share (2019-2020)
Table 52. Japan Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2015-2020) (Million US$)
Table 53. Japan Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Type (2015-2020)
Table 54. Japan Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2015-2020) (Million US$)
Table 55. Japan Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Application (2015-2020)
Table 56. Southeast Asia Key Players Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (2019-2020) (Million US$)
Table 57. Southeast Asia Key Players Hemophilia A and B Recombinant Factor Replacement Therapy Market Share (2019-2020)
Table 58. Southeast Asia Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2015-2020) (Million US$)
Table 59. Southeast Asia Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Type (2015-2020)
Table 60. Southeast Asia Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2015-2020) (Million US$)
Table 61. Southeast Asia Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Application (2015-2020)
Table 62. India Key Players Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (2019-2020) (Million US$)
Table 63. India Key Players Hemophilia A and B Recombinant Factor Replacement Therapy Market Share (2019-2020)
Table 64. India Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2015-2020) (Million US$)
Table 65. India Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Type (2015-2020)
Table 66. India Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2015-2020) (Million US$)
Table 67. India Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Application (2015-2020)
Table 68. Central & South America Key Players Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (2019-2020) (Million US$)
Table 69. Central & South America Key Players Hemophilia A and B Recombinant Factor Replacement Therapy Market Share (2019-2020)
Table 70. Central & South America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type (2015-2020) (Million US$)
Table 71. Central & South America Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Type (2015-2020)
Table 72. Central & South America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application (2015-2020) (Million US$)
Table 73. Central & South America Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Application (2015-2020)
Table 74. Pfizer Company Details
Table 75. Pfizer Business Overview
Table 76. Pfizer Product
Table 77. Pfizer Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2015-2020) (Million US$)
Table 78. Pfizer Recent Development
Table 79. Novo Nordisk Company Details
Table 80. Novo Nordisk Business Overview
Table 81. Novo Nordisk Product
Table 82. Novo Nordisk Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2015-2020) (Million US$)
Table 83. Novo Nordisk Recent Development
Table 84. Baxalta Company Details
Table 85. Baxalta Business Overview
Table 86. Baxalta Product
Table 87. Baxalta Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2015-2020) (Million US$)
Table 88. Baxalta Recent Development
Table 89. Bayer Company Details
Table 90. Bayer Business Overview
Table 91. Bayer Product
Table 92. Bayer Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2015-2020) (Million US$)
Table 93. Bayer Recent Development
Table 94. Biogen Company Details
Table 95. Biogen Business Overview
Table 96. Biogen Product
Table 97. Biogen Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2015-2020) (Million US$)
Table 98. Biogen Recent Development
Table 99. CSL Behring Company Details
Table 100. CSL Behring Business Overview
Table 101. CSL Behring Product
Table 102. CSL Behring Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2015-2020) (Million US$)
Table 103. CSL Behring Recent Development
Table 104. Emergent Biosolutions Company Details
Table 105. Emergent Biosolutions Business Overview
Table 106. Emergent Biosolutions Product
Table 107. Emergent Biosolutions Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2015-2020) (Million US$)
Table 108. Emergent Biosolutions Recent Development
Table 109. Spark therapeutics Business Overview
Table 110. Spark therapeutics Product
Table 111. Spark therapeutics Company Details
Table 112. Spark therapeutics Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2015-2020) (Million US$)
Table 113. Spark therapeutics Recent Development
Table 114. Uniqure Company Details
Table 115. Uniqure Business Overview
Table 116. Uniqure Product
Table 117. Uniqure Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy Business (2015-2020) (Million US$)
Table 118. Uniqure Recent Development
Table 119. Research Programs/Design for This Report
Table 120. Key Data Information from Secondary Sources
Table 121. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Type: 2020 VS 2026
Figure 2. Haemophilia A Features
Figure 3. Haemophilia B Features
Figure 4. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Application: 2020 VS 2026
Figure 5. Hospitals Case Studies
Figure 6. Clinics Case Studies
Figure 7. AmbulatorySurgicalCenters Case Studies
Figure 8. Hemophilia A and B Recombinant Factor Replacement Therapy Report Years Considered
Figure 9. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth 2015-2026 (US$ Million)
Figure 10. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Regions: 2020 VS 2026
Figure 11. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Regions (2021-2026)
Figure 12. Porter's Five Forces Analysis
Figure 13. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Share by Players in 2019
Figure 14. Global Top Hemophilia A and B Recombinant Factor Replacement Therapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy as of 2019
Figure 15. The Top 10 and 5 Players Market Share by Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in 2019
Figure 16. North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. China Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Japan Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Southeast Asia Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. India Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Central & South America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Bottom-up and Top-down Approaches for This Report
Figure 24. Data Triangulation
Figure 25. Key Executives Interviewed

以下、関連資料のご紹介
  • 持続的腎代替療法（CRRT）の世界市場（～2026年）
    Global Continuous Renal Replacement Therapy (CRRT) Market Size, Status and Forecast 2020-2026
    MRC2-11QY11494 2020年11月25日 127Pages
    当調査資料は持続的腎代替療法（CRRT）のグローバル市場について調査・分析したレポートです。種類別（透析液・補液、使い捨て用品、ブラッドラインセット、ヘモフィルター、その他）市場規模、用途別（低速持続的限外濾過（SCUF）、持続的静脈静脈血液濾過（CVVH）、連続静脈静脈血液透析（CVVHD）、連続...
  • 血友病治療薬の世界市場（～2026年）
    Global Hemophilia Treatment Drugs Market Insights and Forecast to 2026
    MRC2-11QY01114 2020年11月20日 114Pages
    当調査資料は血友病治療薬のグローバル市場について調査・分析したレポートです。種類別（組換え凝固因子濃縮物、血漿由来凝固因子濃縮物、デスモプレシン、抗線溶薬）市場規模、用途別（病院薬局、小売薬局、Eコマース）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア...
  • 第IX因子欠乏症治療の世界市場（～2026年）
    Global Factor IX Deficiency Treatment Market Size, Status and Forecast 2020-2026
    MRC2-11QY11918 2020年11月25日 96Pages
    当調査資料は第IX因子欠乏症治療のグローバル市場について調査・分析したレポートです。種類別（血友病B、血友病B阻害剤）市場規模、用途別（病院、クリニック、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オースト...
  • 組換え凝固因子の世界市場（～2026年）
    Global Recombinant Coagulation Factors Market Size, Status and Forecast 2020-2026
    MRC2-11QY04468 2020年11月20日 98Pages
    当調査資料は組換え凝固因子のグローバル市場について調査・分析したレポートです。種類別（リコンビナントファクターVIII、リコンビナントファクターIX、フォンウィルブランドファクター）市場規模、用途別（病院、診療所、研究機関）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス...
  • 血友病A・B治療材料の世界市場（～2026年）
    Global Hemophillia A and B Therapeutics Materials Market Size, Status and Forecast 2020-2026
    MRC2-11QY12159 2020年11月25日 92Pages
    当調査資料は血友病A・B治療材料のグローバル市場について調査・分析したレポートです。種類別（デスモプレシン、オクトコガルファ、ノナコガルファ、その他）市場規模、用途別（歯科医院、病院、外来手術センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、ア...
  • 第VIII因子欠乏症治療の世界市場（～2026年）
    Global Factor VIII Deficiency Treatment Market Size, Status and Forecast 2020-2026
    MRC2-11QY11919 2020年11月25日 129Pages
    当調査資料は第VIII因子欠乏症治療のグローバル市場について調査・分析したレポートです。種類別（血友病A薬、血友病A阻害剤治療、フォンウィルブランド病治療）市場規模、用途別（病院、クリニック、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジ...
  • 血友病薬の世界市場（～2026年）
    Global Hemophilia Drugs Market Insights and Forecast to 2026
    MRC2-11QY01113 2020年11月20日 119Pages
    当調査資料は血友病薬のグローバル市場について調査・分析したレポートです。種類別（血友病A、阻害剤、血友病B、フォンウィルブランド病）市場規模、用途別（組換え療法、血漿由来療法）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、イ...
  • 組換えヒトアルブミンの世界市場（～2026年）
    Global Recombinant Human Albumin Market Size, Status and Forecast 2020-2026
    MRC2-11QY04470 2020年11月20日 98Pages
    当調査資料は組換えヒトアルブミンのグローバル市場について調査・分析したレポートです。種類別（OsrHSA、ScrHSA）市場規模、用途別（細胞培養培地、医療サプリメント、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、...
  • 人工股関節全置換術の世界市場（～2026年）
    Global Total Hip Replacement Market Size, Status and Forecast 2020-2026
    MRC2-11QY04868 2020年11月20日 91Pages
    当調査資料は人工股関節全置換術のグローバル市場について調査・分析したレポートです。種類別（金属材料、合金材料、樹脂材料）市場規模、用途別（45歳以下、45〜65歳、65歳以上）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、イ...
  • 直接前股関節置換術の世界市場（～2026年）
    Global Direct Anterior Hip Replacement Market Size, Status and Forecast 2020-2026
    MRC2-11QY11678 2020年11月25日 97Pages
    当調査資料は直接前股関節置換術のグローバル市場について調査・分析したレポートです。種類別（金属材料、合金材料、樹脂材料）市場規模、用途別（45歳以下、45〜65歳、65歳以上）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、イ...
  • 第IX因子欠乏症治療の世界市場（～2026年）第IX因子欠乏症治療の世界市場（～2026年） Factor IX (or Christmas factor) is one of the serine proteases of the coagulation system; it belongs to peptidase family S1. Deficiency of this protein causes hemophilia B. In this market study, analysts have estimated the prophylaxis segment to dominate the factor IX deficiency treatment market dur…
  • 持続的腎代替療法（CRRT）の世界市場（～2026年）持続的腎代替療法（CRRT）の世界市場（～2026年） This Continuous Renal Replacement Therapy (CRRT) market is segmented based on product, and modality. On the basis of product, the Continuous Renal Replacement Therapy (CRRT) market is segmented into CRRT systems, disposables, and dialysates & replacement fluids, in which dialysates and replacement f…
  • 組換え凝固因子の世界市場（～2026年）組換え凝固因子の世界市場（～2026年） Recombinant coagulation factors are plasma derived counterparts used to treat infection from viruses such as hepatitis C and the human immunodeficiency virus. In addition, recombinant coagulation factors have low risk for transmission of infectious agents. Market Analysis and Insights: Global Recomb…
  • 血友病治療薬の世界市場（～2026年）血友病治療薬の世界市場（～2026年） Hemophilia is a rare disorder in which your blood doesn't clot normally because it lacks sufficient blood-clotting proteins (clotting factors). Market Analysis and Insights: Global Hemophilia Treatment Drugs Market The global Hemophilia Treatment Drugs market size is projected to reach US$ 11160 mil…
  • 第VIII因子欠乏症治療の世界市場（～2026年）第VIII因子欠乏症治療の世界市場（～2026年） Factor VIII is an essential blood-clotting protein, which is also known as an antihemophilic factor. In individuals, factor VIII is encoded by F8 gene. Defects in F8 gene lead to hemophilia A, a recessive X-linked coagulation disorder. Factor VIII is generated in liver sinusoidal cells and endotheli…